- Home
- CABA vs SATX Comparison
CABA vs SATX Comparison
Compare CABA & SATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- SATX
- Stock Information
- Founded
- CABA 2017
- SATX 2012
- Country
- CABA United States
- SATX Israel
- Employees
- CABA N/A
- SATX N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- SATX Radio And Television Broadcasting And Communications Equipment
- Sector
- CABA Health Care
- SATX Technology
- Exchange
- CABA Nasdaq
- SATX Nasdaq
- Market Cap
- CABA 118.8M
- SATX 130.6M
- IPO Year
- CABA 2019
- SATX N/A
- Fundamental
- Price
- CABA $2.58
- SATX $1.43
- Analyst Decision
- CABA Strong Buy
- SATX Strong Buy
- Analyst Count
- CABA 9
- SATX 2
- Target Price
- CABA $27.22
- SATX $2.25
- AVG Volume (30 Days)
- CABA 1.6M
- SATX 461.3K
- Earning Date
- CABA 11-14-2024
- SATX 02-14-2025
- Dividend Yield
- CABA N/A
- SATX N/A
- EPS Growth
- CABA N/A
- SATX N/A
- EPS
- CABA N/A
- SATX N/A
- Revenue
- CABA N/A
- SATX $10,351,000.00
- Revenue This Year
- CABA N/A
- SATX $80.62
- Revenue Next Year
- CABA N/A
- SATX N/A
- P/E Ratio
- CABA N/A
- SATX N/A
- Revenue Growth
- CABA N/A
- SATX N/A
- 52 Week Low
- CABA $1.76
- SATX $0.33
- 52 Week High
- CABA $26.35
- SATX $2.39
- Technical
- Relative Strength Index (RSI)
- CABA 51.37
- SATX 52.37
- Support Level
- CABA $1.94
- SATX $1.21
- Resistance Level
- CABA $2.85
- SATX $1.54
- Average True Range (ATR)
- CABA 0.26
- SATX 0.26
- MACD
- CABA 0.07
- SATX -0.04
- Stochastic Oscillator
- CABA 72.29
- SATX 26.08
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
About SATX SatixFy Communications Ltd.
SatixFy Communications Ltd develops end-to-end next-generation satellite communications systems, including satellite payloads, user terminals and modems, based on powerful chipsets that it develops in house. Its products include modems that feature Software Defined Radio and Fully Electronically Steered Multi Beam Antennas that support the advanced communications standard DVB-S2X. Geographical presence in U.S, Canada, UK and Other countries. Majority of its company revenue comes from U.S and Canada.